Ollin nets $330M to fund Phase 3 trials of Vabysmo challenger from China (OLN324)

Ollin Biosciences has raised an oversubscribed $330 million Series B financing to fund global Phase 3 trials of OLN324, a VEGF/Ang2 bispecific antibody challenging Roche's Vabysmo (faricimab). The financing, received just a year after Ollin's $100 million Series A, is co‑led by TCGX and founding investor ARCH Venture Partners, with participation from major healthcare investors and sovereign funds. The Phase 3 trials will focus on diabetic macular edema (DME) and wet age‑related macular degeneration (wAMD), launching in the second half of 2026 after the Phase 1b JADE head‑to‑head study showed OLN324 produced faster and greater retinal drying and numerically greater vision gains versus Vabysmo. OLN324 originated at Shanghai’s Innovent Biologics and is being developed in partnership with Ollin in Austin, Texas.